Diskussion zur BICO Group Aktie WKN: A2PX00 ISIN: SE0013647385 Forum: Aktien User: Hedgehog3

Sind die Nachrichten gut oder schlecht?

Sind die Nachrichten gut oder schlecht?

TheNeo: Mit dem Nanoscribe verkauf sind die nicht mal ansatzweise schuldenfrei! Ich werte die 20% Entlassung bei Cellink als sehr gut :)

CELLINK announces further right-sizing and launches sharpened commercial agenda CELLINK Bioprinting AB (“CELLINK”), an operating company within the BICO Group AB (“BICO”), has today launched a plan for long-term stability and profitability. This entails a sharpened commercial agenda and further right-sizing to achieve a sustainable cost structure. Measures taken will result in a solid platform to scale from and lay the foundation for sustainable profitable growth. It will also entail an increased focus on the technologies where CELLINK has a leading market position and to optimize synergies with other BICO companies, which is in line with the Group’s updated strategy which was launched during the Capital Market’s Day in Mid-September 2024. “This is aligned with the Group’s updated commercial strategy and our financial targets. This will sharpen CELLINK’s commercial offering and support our transformation and ensure long-term sustainable profitable growth”, says Maria Forss, President and CEO, BICO Group AB. The rightsizing is expected to result in redundancy of approximately 20 percent of the employees across the CELLINK organization. Redundancies are subject to union negotiations. “These measures will enable us to further develop the business on its scientific and commercial strengths. CELLINK will move forward as a tighter and a more cost-effective organization with a continued focus on our key priorities”, says Stefan Blomsterberg, CEO CELLINK Bioprinting AB.

CELLINK announces further right-sizing and launches sharpened commercial agenda CELLINK Bioprinting AB (“CELLINK”), an operating company within the BICO Group AB (“BICO”), has today launched a plan for long-term stability and profitability. This entails a sharpened commercial agenda and further right-sizing to achieve a sustainable cost structure. Measures taken will result in a solid platform to scale from and lay the foundation for sustainable profitable growth. It will also entail an increased focus on the technologies where CELLINK has a leading market position and to optimize synergies with other BICO companies, which is in line with the Group’s updated strategy which was launched during the Capital Market’s Day in Mid-September 2024. “This is aligned with the Group’s updated commercial strategy and our financial targets. This will sharpen CELLINK’s commercial offering and support our transformation and ensure long-term sustainable profitable growth”, says Maria Forss, President and CEO, BICO Group AB. The rightsizing is expected to result in redundancy of approximately 20 percent of the employees across the CELLINK organization. Redundancies are subject to union negotiations. “These measures will enable us to further develop the business on its scientific and commercial strengths. CELLINK will move forward as a tighter and a more cost-effective organization with a continued focus on our key priorities”, says Stefan Blomsterberg, CEO CELLINK Bioprinting AB.